Open AccessBreast cancer in schizophrenia could be interleukin-33-mediated
Author(s) -
M. Borovcanin,
Katarina Vesić
Publication year - 2021
Publication title -
world journal of psychiatry
Language(s) - English
Resource type - Journals
ISSN - 2220-3206
DOI - 10.5498/wjp.v11.i11.1065
Subject(s) - breast cancer , schizophrenia (object oriented programming) , medicine , raloxifene , tamoxifen , cancer , bioinformatics , estrogen receptor , selective estrogen receptor modulator , oncology , psychiatry , biology
Recent epidemiological and genetic studies have revealed an interconnection between schizophrenia and breast cancer. The mutual underlying pathophysiological mechanisms may be immunologically driven. A new cluster of molecules called alarmins may be involved in sterile brain inflammation, and we have already reported the potential impact of interleukin-33 (IL-33) on positive symptoms onset and the role of its soluble trans-membranes full length receptor (sST2) on amelioration of negative symptoms in schizophrenia genesis. Furthermore, these molecules have already been shown to be involved in breast cancer etiopathogenesis. In this review article, we aim to describe the IL-33/suppressor of tumorigenicity 2 (ST2) axis as a crossroad in schizophrenia-breast cancer comorbidity. Considering that raloxifene could be tissue-specific and improve cognition and that tamoxifen resistance in breast carcinoma could be improved by strategies targeting IL-33, these selective estrogen receptor modulators could be useful in complementary treatment. These observations could guide further somatic, as well as psychiatric therapeutical protocols by incorporating what is known about immunity in schizophrenia.